Our blog
Resources and insights
The latest industry news, interviews, technologies, and resources.
Blog categories
Blog
Myotilin
Myotilin is a muscle protein encoded by the MYOT gene. Myotilin is a structural protein of muscle that localizes to the Z discs. Myotilin contains two Immunoglobulin-like (Ig-like) domains similar to those of palladin, myopalladin, titin, and other proteins. The amino-terminal portion of myotilin contains a large number of serine residues and is not similar to any other known protein.Human patients with Limb-Girdle Muscular Dystrophy (LGMD) or Myofibrillar Myopathy (MFM) have been found to have mutations in MYOT. Both LGMD and MFM are disease states associated with mutations in a number of different genes. A substantial fraction of human patients with LGMD or MFM do not receive a molecular diagnosis, suggesting that there are undiscovered genetic variants responsible for some of these cases.Human patients with LGMD that have mutations in MYOT are diagnosed with Limb-Girdle Muscular Dystrophy 1A (LGMD1A), while human patients with MFM that have mutations in MYOT are diagnosed with Myofibrillar Myopathy 3 (MFM3). Pathogenic mutations in MYOT are dominant missense alleles. Known pathogenic alleles include S55F, T57I, S60C, S60F, and S95I [1, 2, 3].There is a substantial difference in the age of onset and the symptoms of human patients with MYOT mutations, even among patients carrying the…
News
EquiSeq adds P8 and K1 to Myopathy Panel
Fayetteville, AR At the Al Khamsa Annual Meeting and Convention today in Fayetteville, Arkansas, EquiSeq announced that it has added the P8 and K1 tests to the Myopathy Panel at no extra cost. EquiSeq’s Myopathy Panel, priced at $249, now includes tests for P2, P3, P4, Px, P8, and K1. The P8 and K1 genetic variants are missense alleles of undisclosed genes of known function. P8 and K1 are known to be pathogenic as a result of EquiSeq’s internal validation process. The genes will be disclosed in a peer-reviewed scientific publication. The P8 genetic variant is prevalent in Arabians, but has also be found in Thoroughbreds, stock breeds (Quarter Horses, Paints, and Appaloosas), Icelandics, and other breeds. The K1 genetic variant is prevalent in Arabians, but has also been found in Morgans, American Miniatures, Haflingers, and Standardbreds. It is rare in stock breeds (Quarter Horses, Paints, and Appaloosas) and appears to be absent in Thoroughbreds. Tests for the P8 and K1 genetic variants will be included at no extra cost in EquiSeq’s Myopathy Panel through January 31, 2020. After that, the price of the Myopathy Panel will increase to $299.
Blog
Arabian MFM
This was written in response to a post on the PSSM Forum on Facebook. Negative nitrogen balance is a normal process that is helpful under the right circumstances. It is not confined to PSSM horses. You have certainly experienced it yourself. There are some circumstances under which you cannot consume enough dietary protein to meet your needs for amino acids. When you have the flu, for example, your immune system is working hard and you need a lot of amino acids to synthesize proteins. Your body tears down muscle in order break protein down into amino acids for use elsewhere. Some of the amino acids are burned for energy. Skeletal or striated muscle is made up of basic units called sarcomeres (part b of the image above shows the structure of a sarcomere). The sarcomere is bounded by Z discs. Attached to the Z disc are thin filaments composed of actin that overlap thick filaments composed of myosin in the center of the sarcomere. When a muscle contracts, the thick filaments slide relative to the thin filaments. Because the thin filaments are anchored to the Z discs, this sliding causes the sarcomere to contract. Myofibrillar Myopathy is a term borrowed from human…
Blog
Polysaccharide Storage Myopathy type 2 (PSSM2)
Polysaccharide Storage Myopathy type 2 (PSSM2) is a type of exercise intolerance seen in horses. Polysaccharide Storage Myopathy type 2 (PSSM2) is a disease state defined by symptoms of exercise intolerance, absence of the genetic variant GYS1-R309H (P1) that is associated with Polysaccharide Storage Myopathy type 1 (PSSM1) [1], and abnormalities observed in muscle biopsy. The PSSM2 disease state was originally defined during investigation of PSSM1, when it was discovered that some horses with exercise intolerance test negative for GYS1-R309H (P1) and lack the enlarged, amylase-resistant glycogen granules seen in muscle biopsies from horses with the GYS1-R309H (P1) variant [2]. Despite a decade of research since PSSM2 was first described, there is no evidence that PSSM2 is a disorder of carbohydrate metabolism. PSSM2 was originally postulated to be a disorder of glycogen metabolism because muscle biopsies of horses with PSSM2 showed clumping of glycogen granules of normal size. A study of Arabian Myofibrillar Myopathy (MFM) showed that the clumping of glycogen granules in regions of myofibrillar disorganization gives the false appearance of a glycogen storage disorder [3]. Several research teams (including EquiSeq) have performed whole genome sequencing on horses diagnosed with PSSM2 and have failed to find any genetic variants…
Blog
Polysaccharide Storage Myopathy type 1 (PSSM1)
Polysaccharide Storage Myopathy type 1 (PSSM1) is a disease state in horses caused by an inherited defect in glycogen metabolism. Polysaccharide Storage Myopathy type 1 (PSSM1) is a form of exercise intolerance. Horses with Polysaccharide Storage Myopathy type 1 (PSSM1) exhibit exercise-induced symptoms including reluctance to move, pain, stiffness, tremors, and profuse sweating. Serum creatine kinase (CK) and aspartate aminotransferase (AST) are elevated, indicating muscle damage. In severe episodes, myoglobinuria (coffee-colored urine due to the presence of myoglobin), inability to stand, and death can occur. Glycogen is a complex polymer of glucose that serves as a store of glucose in liver and skeletal muscle. As shown in the image below, a glycogen granule consists of multiple branched chains of glucose units. Most of the glucose units are joined by a-1,4 linkages, with a-1,6 linkages at the branch points. The synthesis and breakdown of glycogen are controlled by different enzymes. Glycogen synthase and the branching enzyme synthesize glycogen, while glycogen phosphorylase and the debranching enzyme break it down. Glycogen synthesis and breakdown is regulated in response to energy needs and the availability of glucose. Muscle biopsy of horses with PSSM1 reveals the presence of enlarged glycogen granules that are amylase-resistant. During…
Blog
Jax
Jax is n/P1, n/P2, n/Px. I got him when he was an unbroke 4 year old, and he was quirky that first year but then had over 2 great years of riding. He didn’t go highly symptomatic until he was 8 years old, but right as he turned 8 he crashed hard. Early symptoms included shaky on trailer rides, sticky stifles when out of work, and on/off lameness. As he became more symptomatic he began urinating small amounts of dark brown at the end of the stream – he did this for about a year before major symptoms, right around the time he became overly spooky and started bolting under saddle. These symptoms progressed to shakiness verging on spasms during trailer rides (has gone into full-blown tie up on longer trailer rides), sticky stifles at all times to the point he could barely trot, lumbar and skin pain that would cause him to drop from pressure, couldn’t hold up legs for farrier, and more drastic behavioral changes (aggression towards pasture mates, rearing during handwalks, crow hopping under saddle – but no full-on bucking, etc.). He started twisting his hind legs when walking, had a strange hitching gait in the back…
Blog
Negative Nitrogen Balance
This was written in response to a post on the PSSM Forum on Facebook. Negative nitrogen balance is a normal process that is helpful under the right circumstances. It is not confined to PSSM horses. You have certainly experienced it yourself. There are some circumstances under which you cannot consume enough dietary protein to meet your needs for amino acids. When you have the flu, for example, your immune system is working hard and you need a lot of amino acids to synthesize proteins. Your body tears down muscle in order break protein down into amino acids for use elsewhere. Some of the amino acids are burned for energy. All amino acids have a chemical structure with a central carbon atom bonded to four different parts: an amino group, a carboxyl group, a hydrogen atom, and an “R” group that is a different group for each amino acid. When an amino acid is burned for energy, one of the first steps is the removal of the amino group. If this is not used to synthesize one of the nonessential amino acids, it is discarded as waste. To do that, it enters a metabolic cycle called the urea cycle and is…
News
UNM Alumni Magazine Features EquiSeq
FASTER HORSES EquiSeq decodes equine genetics for better health and performanceBy Leslie Linthicum At the core of most living things is the genome, the package of genetic materials stored in long molecules of DNA. It’s what makes a person, a whale or a blob of algae grow and develop different characteristics. And it is at the core of developing more effective disease treatments and cures. Scientists around the world have collaborated to map the human genome and continue to work in laboratories to tease out longer pieces of DNA and more complete genomes and to apply genomic discoveries to helping mankind. UNM Professor Jeremy Edwards and retired biology Professor Paul Szauter pursue those ideals, but they also apply those same scientific questions and techniques to horses. Partners in the Albuquerque-based startup EquiSeq, they have already patented and licensed four genetic tests that will allow breeders to screen for common but devastating muscle diseases in horses. And they have hit on a trade secret that could revolutionize Thoroughbred racehorse breeding. It began with a simple question: What made Secretariat, the fastest horse in racing history, run so fast? The answer is that his heart was more than twice the size of…
News
Center for Animal Genetics licenses new genetic tests for horses from EquiSeq
Tuebingen CAG GmbH – Center for Animal Genetics has signed an agreement with EquiSeq to be the exclusive testing center for their Equine Myopathy Panel in Europe. Horse owners can now test their animals without requiring an invasive blood draw or muscle biopsy. Equine Myopathy Panel tests for mutations in three genes associated with Polysaccharide Storage Myopathy type 2 (PSSM2) and a mutation in one gene associated with Recurrent Exertional Rhabdomyolysis (RER). These mutations have been detected in affected horses of many breeds, including Quarter Horses, Thoroughbreds, Warmbloods, Arabians, Gaited Horses, Draft Horses, and many pony breeds. Affected horses often do not show symptoms until they have already been used for breeding or have had many years of investment in training. Using genetic testing, owners and breeders can identify an affected horse prior to breeding or extensive training for sport. Veterinarians and other horse health professionals can make specific diagnoses and management plans. Although the diseases cannot be cured, a horse’s quality of life can be substantially improved with a correct diagnosis and the development of an appropriate management plan. More information about the disease and tests can be found on the CAG website . Tests can be ordered and paid for…
News
EquiSeq Names New CEO, Signs Licensing Deal with CAG.
By Collin Krabbe – Technology reporter , Albuquerque Business FirstJul 23, 2018, 2:33pm MDT Albuquerque-based biotechnology company EquiSeq has been busy with two new developments: the hire of a new chief executive and a fresh licensing agreement. Alex Hafez is the firm’s new CEO. He is pursuing a dual-degree from the University of New Mexico in business administration and biomedical science. “I think research is really interesting… [but] I’m more interested in management of biotech companies,” Hafez said. “Growing up, I’ve always found myself in positions of leadership.” The 26-year-old Oregon native said being educated in both the business and science fields gives him a different perspective on the cost of conducting research and development for a private company. The new CEO will not earn a salary in his new position, but will rather be given an undisclosed amount of equity in the company. Business First reported in January that the firm’s previous CEO, Lexi Palmer stepped down due to concerns about the distribution of funds in Albuquerque’s startup scene. Hafez said his appointment comes at an exciting time for EquiSeq, which produces genetic tests for horses. The firm just entered into an exclusive licensing agreement with Germany’s Center for…